News | August 06, 2024
OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
Revolutionary technology will further boost OneSource’s scientific services offerings
Revolutionary technology will further boost OneSource’s scientific services offerings
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Executes the first project for developing and manufacturing a novel anticancer mAb
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Additional capacity broadens Grace’s fine chemical capabilities for API production
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Subscribe To Our Newsletter & Stay Updated
